Avidity Partners Management LP
Long book
$935.7M
Q1 2026
Positions
52
Top-10 weight
81%
concentration
Last quarter
+20.2%
SPY +14.8%
Turnover
64%
of book per quarter
Strategy in plain words
auto-generated from filingsAvidity Partners Management LP is a diversified fundamental manager, specialised in healthcare (98% of the long book), running a $935.7M US long book across 52 positions.
The portfolio is extremely concentrated — the top 10 positions are almost the whole book. Turnover is high — positions rotate quickly, so individual names matter less than the process. Current anchor positions: DIANTHUS THERAPEUTICS INC, ORUKA THERAPEUTICS INC, CG ONCOLOGY INC, JADE BIOSCIENCES INC, PERSPECTIVE THERAPEUTICS INC.
Over the last 9 quarters its long book ran on average 3.5pp per quarter ahead of the S&P 500, beating the index in 5 of 9 quarters. We rate its filings as signal-bearing: position changes reflect genuine views.
Implied long-book return vs S&P 500
methodology: positions priced quarterly, no shorts/options Fund long book S&P 500
Q1 2024
-7.1%
Q2 2024
+9.1%
Q3 2024
-12.5%
Q4 2024
-13.3%
Q1 2025
+1.0%
Q2 2025
+22.3%
Q3 2025
+11.9%
Q4 2025
+40.5%
Q1 2026
+20.2%
Sector allocation
Healthcare 98%
Financials 1%
Other 1%
Technology 1%
Materials 0%
Long book by quarter
What does Avidity Partners own?
Q1 2026 13F| Company | Sector | Shares | Value | % of book | Change |
|---|---|---|---|---|---|
| DNTH DIANTHUS THERAPEUTICS INC | Healthcare | 4.2M | $361.3M | 38.6% | +100.0% |
| ORKA ORUKA THERAPEUTICS INC | Healthcare | 1.5M | $89.3M | 9.5% | +130.3% |
| CGON CG ONCOLOGY INC | Healthcare | 1.3M | $87.2M | 9.3% | -12.5% |
| JBIO JADE BIOSCIENCES INC | Healthcare | 2.8M | $53.9M | 5.8% | +100.0% |
| CATX PERSPECTIVE THERAPEUTICS INC | Healthcare | 12.1M | $48.8M | 5.2% | +276.9% |
| ELVN ENLIVEN THERAPEUTICS INC | Healthcare | 800.0K | $32.2M | 3.4% | +470.2% |
| CNTX CONTEXT THERAPEUTICS INC | Healthcare | 10.0M | $24.9M | 2.7% | +81.6% |
| RGEN REPLIGEN CORP | Healthcare | 155.6K | $18.4M | 2.0% | +209.3% |
| PVLA PALVELLA THERAPEUTICS INC | Healthcare | 140.0K | $17.7M | 1.9% | +625.4% |
| AKTS AKTIS ONCOLOGY INC | Healthcare | 937.1K | $17.2M | 1.8% | New |
| MDT MEDTRONIC PLC | Healthcare | 200.0K | $16.8M | 1.8% | +85.9% |
| VIR VIR BIOTECHNOLOGY INC | Healthcare | 1.6M | $14.8M | 1.6% | New |
| IMUX IMMUNIC INC | Healthcare | 7.4M | $13.9M | 1.5% | +56.8% |
| DXCM DEXCOM INC | Healthcare | 190.0K | $11.6M | 1.2% | New |
| EHC ENCOMPASS HEALTH CORP | Healthcare | 84.0K | $8.3M | 0.9% | +165.8% |
| BSX BOSTON SCIENTIFIC CORP | Healthcare | 120.0K | $7.2M | 0.8% | +4.8% |
| TENX TENAX THERAPEUTICS INC | Healthcare | 481.9K | $6.9M | 0.7% | New |
| KPTI KARYOPHARM THERAPEUTICS INC | Healthcare | 927.5K | $6.4M | 0.7% | +589.2% |
| HUM HUMANA INC | Financials | 25.0K | $5.9M | 0.6% | New |
| PHAT PHATHOM PHARMACEUTICALS INC | Healthcare | 498.8K | $5.6M | 0.6% | +142.0% |
| GILD GILEAD SCIENCES INC | Healthcare | 40.0K | $5.4M | 0.6% | New |
| MSLE SATELLOS BIOSCIENCE INC | Healthcare | 775.5K | $5.3M | 0.6% | New |
| TEM TEMPUS AI INC-CL A | Technology | 90.0K | $4.7M | 0.5% | New |
| SCYX SCYNEXIS INC | Healthcare | 4.2M | $3.8M | 0.4% | +100.0% |
| ICLR ICON PLC | Healthcare | 32.0K | $3.7M | 0.4% | -3.3% |
| NTRA NATERA INC | Healthcare | 18.0K | $3.7M | 0.4% | +52.5% |
| CRVS CORVUS PHARMACEUTICALS INC | Healthcare | 230.0K | $3.4M | 0.4% | New |
| HIMS HIMS & HERS HEALTH INC | Healthcare | 125.0K | $2.9M | 0.3% | New |
| CORT CORCEPT THERAPEUTICS INC | Healthcare | 60.0K | $2.6M | 0.3% | +172.7% |
| CNC CENTENE CORP | Financials | 70.0K | $2.3M | 0.2% | -41.4% |
| NTLA INTELLIA THERAPEUTICS INC | Materials | 150.0K | $2.0M | 0.2% | New |
| PTON PELOTON INTERACTIVE INC-A | Other | 400.0K | $1.9M | 0.2% | New |
| ODD ODDITY TECH LTD-CL A | Other | 140.0K | $1.9M | 0.2% | New |
| AVR ANTERIS TECHNOLOGIES GLOBAL | Healthcare | 300.0K | $1.8M | 0.2% | New |
| MLTX MOONLAKE IMMUNOTHERAPEUTICS | Healthcare | 100.0K | $1.8M | 0.2% | New |
| KVUE KENVUE INC | Other | 100.0K | $1.7M | 0.2% | -57.0% |
| PODD INSULET CORP | Healthcare | 10.0K | $1.7M | 0.2% | New |
| CRL CHARLES RIVER LABORATORIES | Healthcare | 10.0K | $1.7M | 0.2% | New |
| RVMD REVOLUTION MEDICINES INC | Healthcare | 15.0K | $1.5M | 0.2% | New |
| ABUS ARBUTUS BIOPHARMA CORP | Healthcare | 250.0K | $1.1M | 0.1% | New |
| UNH UNITEDHEALTH GROUP INC | Financials | 3.8K | $1.0M | 0.1% | New |
| ABT ABBOTT LABORATORIES | Healthcare | 10.0K | $908K | 0.1% | New |
| BBOT BRIDGEBIO ONCOLOGY THERAPEUT | Healthcare | 87.7K | $761K | 0.1% | New |
| BBIO BRIDGEBIO PHARMA INC | Healthcare | 10.0K | $711K | 0.1% | New |
| ACAD ACADIA PHARMACEUTICALS INC | Healthcare | 25.9K | $580K | 0.1% | -75.7% |
| SVRA SAVARA INC | Healthcare | 50.0K | $262K | 0.0% | New |
| TRVI TREVI THERAPEUTICS INC | Healthcare | 13.3K | $171K | 0.0% | New |
13F filing history
| Period | Form | Filed | Entries | Reported value | Flags | Source |
|---|---|---|---|---|---|---|
| Q1 2026 | 13F-HR/ANEW HOLDINGS | May 28, 2026 | 45 | $493.8M | canonical | SEC ↗ |
| Q1 2026 | 13F-HR | May 13, 2026 | 46 | $441.9M | canonical | SEC ↗ |
| Q4 2025 | 13F-HR | Feb 13, 2026 | 39 | $346.7M | canonical | SEC ↗ |
| Q3 2025 | 13F-HR | Nov 14, 2025 | 43 | $439.4M | canonical | SEC ↗ |
| Q2 2025 | 13F-HR | Aug 14, 2025 | 56 | $502.0M | canonical | SEC ↗ |
| Q1 2025 | 13F-HR | May 15, 2025 | 67 | $524.7M | canonical | SEC ↗ |
| Q4 2024 | 13F-HR | Feb 14, 2025 | 63 | $1.02B | canonical | SEC ↗ |
| Q3 2024 | 13F-HR | Nov 14, 2024 | 81 | $1.96B | canonical | SEC ↗ |
| Q2 2024 | 13F-HR | Aug 14, 2024 | 85 | $2.35B | canonical | SEC ↗ |
| Q1 2024 | 13F-HR | May 15, 2024 | 90 | $3.10B | canonical | SEC ↗ |